Skip to content

Study · Randomized controlled trial · n = 52 · 2019

4 results

The influence of oxytocin on eating behaviours and stress in women with bulimia nervosa and binge eating disorder.

Leslie M, Leppanen J, Paloyelis Y, Treasure J

Molecular and cellular endocrinology21 Dec 2018Cited by 20 (Europe PMC)

PMID30579958 (opens in a new tab)DOI10.1016/j.mce.2018.12.014 (opens in a new tab)PepBankPUB-30579958
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with bulimia nervosa or binge eating disorder and in comparison women, intranasal oxytocin had no significant effect on eating behaviour measures such as palatable food intake compared with placebo.

    In plain wordsIn women with and without eating disorders, oxytocin did not change how much tasty food they ate compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changePalatable food intake
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    64 IU (divided dose) · intranasalAs given in this study (human).

    Source sentences

    Summary
    We did not find a significant effect of oxytocin on any of the measurements of eating behaviour, subjective stress, or salivary cortisol.
    3 context sentences
    Summary · context
    The current study aimed to test the influence of oxytocin on palatable food intake, 24-h caloric consumption, and stress in women with bulimia nervosa and binge eating disorder.
    Summary · context
    We recruited 25 women with DSM-5 bulimia nervosa or binge eating disorder, and 27 weight-matched comparison women without history of an eating disorder.
    Summary · context
    We employed a double-blind, placebo-controlled crossover design in which each participant attended the lab for two experimental sessions, receiving a divided dose of 64IU intranasal oxytocin in one session and equivalent volume of placebo nasal spray in the opposite session.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with bulimia nervosa or binge eating disorder and in comparison women, intranasal oxytocin had no significant effect on 24-h caloric consumption compared with placebo.

    In plain wordsIn women with and without eating disorders, oxytocin did not change the calories they ate over 24 hours compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant change24-hour caloric consumption
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Mental health and mood
    Studied dose
    64 IU (divided dose) · intranasalAs given in this study (human).

    Source sentences

    Summary
    We did not find a significant effect of oxytocin on any of the measurements of eating behaviour, subjective stress, or salivary cortisol.
    3 context sentences
    Summary · context
    The current study aimed to test the influence of oxytocin on palatable food intake, 24-h caloric consumption, and stress in women with bulimia nervosa and binge eating disorder.
    Summary · context
    We recruited 25 women with DSM-5 bulimia nervosa or binge eating disorder, and 27 weight-matched comparison women without history of an eating disorder.
    Summary · context
    We employed a double-blind, placebo-controlled crossover design in which each participant attended the lab for two experimental sessions, receiving a divided dose of 64IU intranasal oxytocin in one session and equivalent volume of placebo nasal spray in the opposite session.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with bulimia nervosa or binge eating disorder and in comparison women, intranasal oxytocin had no significant effect on subjective stress compared with placebo.

    In plain wordsIn women with and without eating disorders, oxytocin did not change how stressed they felt compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSubjective stress
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    64 IU (divided dose) · intranasalAs given in this study (human).

    Source sentences

    Summary
    We did not find a significant effect of oxytocin on any of the measurements of eating behaviour, subjective stress, or salivary cortisol.
    2 context sentences
    Summary · context
    We recruited 25 women with DSM-5 bulimia nervosa or binge eating disorder, and 27 weight-matched comparison women without history of an eating disorder.
    Summary · context
    We employed a double-blind, placebo-controlled crossover design in which each participant attended the lab for two experimental sessions, receiving a divided dose of 64IU intranasal oxytocin in one session and equivalent volume of placebo nasal spray in the opposite session.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with bulimia nervosa or binge eating disorder and in comparison women, intranasal oxytocin had no significant effect on salivary cortisol compared with placebo.

    In plain wordsIn women with and without eating disorders, oxytocin did not change saliva cortisol compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSalivary cortisol
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    64 IU (divided dose) · intranasalAs given in this study (human).

    Source sentences

    Summary
    We did not find a significant effect of oxytocin on any of the measurements of eating behaviour, subjective stress, or salivary cortisol.
    2 context sentences
    Summary · context
    We recruited 25 women with DSM-5 bulimia nervosa or binge eating disorder, and 27 weight-matched comparison women without history of an eating disorder.
    Summary · context
    We employed a double-blind, placebo-controlled crossover design in which each participant attended the lab for two experimental sessions, receiving a divided dose of 64IU intranasal oxytocin in one session and equivalent volume of placebo nasal spray in the opposite session.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.